Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Generic Pharmaceuticals Contract Manufacturing market was valued at USD 63.18 billion in 2021 and it is expected to hit around USD 107.9 billion by 2030 with a CAGR of 5.17% during the forecast period 2022 to 2030.

https://www.novaoneadvisor.com/reportimg/Generic-Pharmaceuticals-Contract-Manufacturing-Market-2022-to-2030.jpg

Key Takeaways:

  • The branded generics segment held the largest share in 2021due to the preference for branded generics among physicians. Some branded generic manufacturers offer benefits and gifts to physicians for boosting their product sales. This further contributes to the demand for branded generic manufacturing in the market
  • The API product segment held the largest share in 2021. The growing demand for generic drugs is supporting the demand for generic API contract manufacturing
  • The parenteral route of administration segment is expected to grow at the fastest CAGR over the forecast period due to the bioavailability of parenteral drugs over other formulations
  • The oncology segment is expected to register the fastest CAGRfrom 2022 to 2030 owing to the high cost of cancer drugs contributing to the demand for cost-effective generic medicines
  • Asia Pacific is expected to record the highest CAGR over the forecast period mainly due to the low cost of generic drug manufacturing

Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

Report Scope of the Generic Pharmaceuticals Contract Manufacturing Market

Report Coverage

Details

Market Size

USD 107.9 Billion by 2030

Growth Rate

CAGR of 5.17% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Drug type, product, route of administration, application and Region,

Companies Mentioned

Jubilant Generics Ltd.; Recipharm AB; Siegfried Holding AG; Aurobindo Pharma; Cambrex Corp.; Alcami Corp., Inc.; Catalent, Inc; Acme Generics Pvt. Ltd.; Syngene International Limited; Pfizer CentreOne; Curia Global, Inc.; Metric Contract Services

 

Drug Type Insights

On the basis of drug types, the global industry has been further categorized into branded generics and non-branded generics. The branded generics segment dominated the global industry in 2021 and accounted for the largest share of more than62.5% of the overall revenue. The segment is anticipated to expand further at the fastest growth rate maintaining its dominant industry position throughout the forecast period. Branded generics are known for their superior quality and doctors usually use branded generics over unbranded, based on past experiences.

The unbranded generics segment is also expected to register a significant growth rate during the forecast period. Unbranded generics are generally cheaper than branded ones. Research published by the NCBI states that branded generics are over 13 times more expensive than unbranded generics, which is one of the key factors supporting the demand for unbranded generics. Unbranded generic drugs are equally safe and effective as branded generics. This is expected to boost their demand over the forecast period.

Product Insights

The API product segment dominated the industry in 2021 and accounted for the highest share of more than 56.7% of the overall revenue. Based on products, the industry has been divided into API and drug products. Growing demand for new geriatric drugs and patent expiry of exclusive small-molecule drugs are two of the key reasons boosting segment growth. Increased interest of public organizations in improving the production of API is further supporting segment growth. For instance, in March 2020, the Indian government set up a multiyear plan, in which, it invested USD 1.3 billion to boost the production of API in the country.

Such initiatives are expected to improve generic API contract manufacturing activities and hence contribute to segment growth. The drug product segment is expected to grow at a steady CAGR over the forecast period. Small molecule drug substances have become more complex, with manufacturing methods becoming more specialized. This supports the demand for a CMO for manufacturing drug products. The adoption of the expansion agreements by the CMO for drug product manufacturing is expected to further support segment growth in the coming years. For instance, in January 2022, Piramal Pharma Solutions added a development/commercial-scale roller compaction technology in its facility in Pennsylvania to expand its capabilities in manufacturing solid dosage forms.

Route Of Administration Insights

On the basis of routes of administration, the global industry has been further categorized into oral, topical, parenteral, and others. The oral route of administration segment dominated the industry in 2021 and accounted for the highest share of more than 59.30% of the overall revenue. The oral route is a self-administering route of administration and does not require a trained physician for drug administration, which is one of the major reasons for the high acceptance of oral formulations. Oral formulations are also considered more flexible in design and are majorly used in treating some common diseases, such as migraine, fever, infectious diseases, and diabetes.

These factors are supporting the demand for the oral route of administration. On the other hand, the parenteral segment is expected to register the fastest growth rate during the forecast period. The high bioavailability of injectable formulations leading to the immediate onset of action is the prime factor for its fastest growth. Apart from this, injectable formulations are preferred if the drugs are poorly absorbed. Moreover, the parenteral formulation is also primarily preferred in cases of medical emergencies, which is further driving the segment growth.

Application Insights

The oncology segment accounted for the highest share of more than 21.15% in 2021. Based on application, the industry is segmented into oncology, immunology, antidiabetic, neurology, anticoagulants, cardiovascular, respiratory, pain, HIV antivirals, and others. Cancer is one of the major causes of death worldwide. According to the World Cancer Research Fund International, over 18.1 million cases of cancer were reported in 2020. The American Cancer Society states that National Cancer Costs are expected to increase in the coming years. It states that spending on cancer care accounted for USD 200.7 billion in 2020 and is expected to rise to USD 245.6 billion by 2030 in America.

This increases the demand for cheaper alternatives like generic drugs for cancer treatment. The immunology segment is expected to grow at a significant CAGR over the forecast period. Immunological disorders include rheumatoid arthritis, Addison disease, psoriasis, Alzheimer's disease, and others. One of the major causes of these diseases is the growing geriatric population. Furthermore, immunological diseases require treatment for a long period. This increases the cost of medications and thus supports the demand for generic medications for treating immunological disorders. These factors are supporting the segment growth.

Regional Insights

The Asia Pacific region dominated the global industry in 2021 and accounted for the maximum share of more than 38.00% of the overall revenue. The region is estimated to expand further at the fastest growth rate maintaining its dominant position in the global industry throughout the forecast period as countries in the region have a GMP-regulated infrastructure for manufacturing drugs. Furthermore, the low costs of manufacturing eventually encourage various pharmaceutical companies in developed economies, such as the U.S., to outsource their manufacturing activities in this region.

This factor also helps boost the market growth in the Asia Pacific region. The North America region also accounted for a considerable share in 2021 and will grow further at a steady CAGR from 2022 to 2030. This can be attributed to the growth of the pharmaceutical industries in the U.S. and Canada. The presence of a large number of major players in this region is expected to contribute significantly to its growth. The growing focus of pharmaceutical companies in the region to outsource non-core operations, such as manufacturing, is further supporting the region’s growth.

Some of the prominent players in the Generic Pharmaceuticals Contract Manufacturing Market include:

  • Jubilant Generics Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Aurobindo Pharma
  • Cambrex Corp.
  • Alcami Corp., Inc.
  • Catalent, Inc.
  • Acme Generics Pvt Ltd.
  • Syngene International Ltd.
  • Pfizer CentreOne
  • Curia Global, Inc.
  • Metric Contract Services

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Generic Pharmaceuticals Contract Manufacturing market

  • Drug Type
    • Branded Generics
    • Unbranded Generics
  • Product
    • API
    • Drug Product
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
    • Others
  • Application
    • Oncology
    • Immunology
    • Antidiabetic
    • Neurology
    • Anticoagulants
    • Cardiovascular
    • Respiratory
    • Pain
    • HIV antivirals
    • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Generic Pharmaceuticals Contract Manufacturing industry analysis from 2022 to 2030 to identify the prevailing Generic Pharmaceuticals Contract Manufacturing industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Generic Pharmaceuticals Contract Manufacturing industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Generic Pharmaceuticals Contract Manufacturing industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7497
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000